356 related articles for article (PubMed ID: 29106324)
1. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
2. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
5. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
6. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
7. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
[TBL] [Abstract][Full Text] [Related]
8. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
9. Review of venom immunotherapy at a regional tertiary paediatric centre.
Johnston N; Belcher J; Preece K; Bhatia R
J Paediatr Child Health; 2022 Jul; 58(7):1228-1232. PubMed ID: 35416342
[TBL] [Abstract][Full Text] [Related]
10. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.
Ewan PW; Deighton J; Wilson AB; Lachmann PJ
Clin Exp Allergy; 1993 Aug; 23(8):647-60. PubMed ID: 8221268
[TBL] [Abstract][Full Text] [Related]
11. [Accelerated desensitization for hymenoptera venom allergy in 30 hours: efficacy and safety in 150 cases].
van der Brempt X; Ledent C; Mairesse M
Rev Med Brux; 1997 Jun; 18(3):120-4. PubMed ID: 9273600
[TBL] [Abstract][Full Text] [Related]
12. Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol.
Rosman Y; Confino-Cohen R; Goldberg A
Int Arch Allergy Immunol; 2017; 174(1):45-51. PubMed ID: 28950273
[TBL] [Abstract][Full Text] [Related]
13. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
14. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
15. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
[TBL] [Abstract][Full Text] [Related]
17. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
[TBL] [Abstract][Full Text] [Related]
18. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
19. Safety of hymenoptera venom immunotherapy: a systematic review.
Incorvaia C; Frati F; Dell'Albani I; Robino A; Cattaneo E; Mauro M; David M; Qualizza R; Pastorello E
Expert Opin Pharmacother; 2011 Nov; 12(16):2527-32. PubMed ID: 21883032
[TBL] [Abstract][Full Text] [Related]
20. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
Sturm G; Kränke B; Rudolph C; Aberer W
J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
